ENTITY
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349 HK)

139
Analysis
Health Care • China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical is primarily engaged in the innovative research and development, production, and marketing of biopharmaceuticals. The company offers a range of products including photodynamic technology drugs like aminolevulinic acid hydrochloride and hemoporfin, doxorubicin liposome under the Libord brand, genetic engineering drugs, and oral solid preparation technology drugs. It is headquartered in Zhangjiang Hi-Tech Park, Pudong, Shanghai, China, and was established in November 1996.
more
•12 Jun 2022 12:19

A-H Premium Weekly: CNOOC, Everbright Sec, Sinopec Oilfield

We highlight week on week A-H premium changes in CNOOC, Everbright Securities, Sinopec Oilfield, Shanghai Fudan, Shandong Xinhua.

Logo
446 Views
Share
•05 Jun 2022 11:53

A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

We highlight A-H premium changes for stocks including Remegen, CNOOC, COSCO Shipping, Cansino, Nanjing Panda, Shenzhen Hepalink, SH Fudan, SH...

Logo
502 Views
Share
•24 Apr 2022 16:43

A-H Premium Weekly: China Southern, Shanghai Junshi, Shanghai Haohai, Shanghai Fudan

A-H premium declined by 5.7ppt last week, real estate, consumer discretionary and information technology led the decline. We highlight China...

Logo
443 Views
Share
•23 Jan 2022 12:18

A/H Premium Weekly: China Comm Construction, China Eastern Air

We highlight three sectors that contributed to the WOW A/H premium decline: consumer staple, consumer discretionary, and information technology,...

Logo
357 Views
Share
•16 Jan 2022 12:29

A/H Premium Weekly: Biggest A/H Premium Declines in a Year

The market average A/H premium registered the biggest declines in the past one year. We highlight top sectors by the decline of A/H premium, as...

Logo
430 Views
Share
x